Cargando…

Osteoprotegerin (OPG) protects ovarian cancer cells from TRAIL-induced apoptosis but does not contribute to malignant ascites-mediated attenuation of TRAIL-induced apoptosis

BACKGROUND: Resistance to apoptosis is a major problem in ovarian cancer and correlates with poor prognosis. Osteoprotegerin (OPG) is a secreted factor in malignant ascites and acts as a decoy receptor for receptor activator of NF-κB ligand (RANKL) and tumor necrosis factor-related apoptosis-inducin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lane, Denis, Matte, Isabelle, Rancourt, Claudine, Piché, Alain
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3507713/ https://www.ncbi.nlm.nih.gov/pubmed/23153223 http://dx.doi.org/10.1186/1757-2215-5-34

Ejemplares similares

Osteoprotegerin (OPG) activates integrin, focal adhesion kinase (FAK), and Akt signaling in ovarian cancer cells to attenuate TRAIL-induced apoptosis
por: Lane, Denis, et al.
Publicado: (2013)

Ovarian cancer ascites increase Mcl-1 expression in tumor cells through ERK1/2-Elk-1 signaling to attenuate TRAIL-induced apoptosis
por: Goncharenko-Khaider, Nadzeya, et al.
Publicado: (2012)

MUC16 mucin (CA125) attenuates TRAIL-induced apoptosis by decreasing TRAIL receptor R2 expression and increasing c-FLIP expression
por: Matte, Isabelle, et al.
Publicado: (2014)

The prosurvival activity of ascites against TRAIL is associated with a shorter disease-free interval in patients with ovarian cancer
por: Lane, Denis, et al.
Publicado: (2010)

The inhibition of Bid expression by Akt leads to resistance to TRAIL-induced apoptosis in ovarian cancer cells
por: Goncharenko-Khaider, N, et al.
Publicado: (2010)

Prognostic significance of IL-6 and IL-8 ascites levels in ovarian cancer patients
por: Lane, Denis, et al.
Publicado: (2011)

Role of malignant ascites on human mesothelial cells and their gene expression profiles
por: Matte, Isabelle, et al.
Publicado: (2014)

Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers
por: Lane, Denis, et al.
Publicado: (2015)

CCL18 from ascites promotes ovarian cancer cell migration through proline-rich tyrosine kinase 2 signaling
por: Lane, Denis, et al.
Publicado: (2016)

Osteoprotegerin and RANKL-RANK-OPG-TRAIL signalling axis in heart failure and other cardiovascular diseases
por: Dutka, Mieczysław, et al.
Publicado: (2021)

N-glycosylation of mouse TRAIL-R restrains TRAIL-induced apoptosis
por: Estornes, Yann, et al.
Publicado: (2018)

Changes in the Concentration of Markers Participating in the Regulation of the Apoptosis Receptor Pathway Involving Soluble Tumour Necrosis Factor Ligand Inducing Apoptosis (sTRAIL) and Osteoprotegerin (OPG) in the Serum of Women with Ovarian Cancer—Participation in Pathogenesis or a Possible Clinical Use?
por: Mielczarek-Palacz, Aleksandra, et al.
Publicado: (2020)

TRAIL-Induced Apoptosis in TRAIL-Resistant Breast Carcinoma Through Quercetin Cotreatment
por: Manouchehri, Jasmine M, et al.
Publicado: (2018)

HDAC2 attenuates TRAIL-induced apoptosis of pancreatic cancer cells
por: Schüler, Susanne, et al.
Publicado: (2010)

Osteoprotegerin and TRAIL in Acute Onset of Atrial Fibrillation
por: Rewiuk, Krzysztof, et al.
Publicado: (2015)

TRAIL-induced rheumatoid arthritis fibroblast-like synoviocyte proliferation is inhibited by OPG
por: Morel, J, et al.
Publicado: (2004)

TRAIL receptor gene editing unveils TRAIL-R1 as a master player of apoptosis induced by TRAIL and ER stress
por: Dufour, Florent, et al.
Publicado: (2016)

Targeting Death Receptor TRAIL-R2 by Chalcones for TRAIL-Induced Apoptosis in Cancer Cells
por: Szliszka, Ewelina, et al.
Publicado: (2012)

TRAIL and curcumin codelivery nanoparticles enhance TRAIL-induced apoptosis through upregulation of death receptors
por: Yang, Xi, et al.
Publicado: (2017)

Roles and Clinical Applications of OPG and TRAIL as Biomarkers in Cardiovascular Disease
por: Bernardi, Stella, et al.
Publicado: (2016)

Dyslipidemia and Diabetes Increase the OPG/TRAIL Ratio in the Cardiovascular System
por: Toffoli, Barbara, et al.
Publicado: (2016)

TRAIL, OPG, and TWEAK in kidney disease: biomarkers or therapeutic targets?
por: Bernardi, Stella, et al.
Publicado: (2019)

TRAIL-β and TRAIL-γ: two novel splice variants of the human TNF-related apoptosis-inducing ligand (TRAIL) without apoptotic potential
por: Krieg, A, et al.
Publicado: (2003)

IL-1 but not IL-18 induces osteoprotegerin and TRAIL in rheumatoid arthritis synovial fibroblasts
por: Morel, J, et al.
Publicado: (2003)

Soluble TRAIL does not impair the anti-osteoclastic activity of osteoprotegerin
por: Zauli, Giorgio, et al.
Publicado: (2008)

Expression of osteoprotegerin and its ligands, RANKL and TRAIL, in rheumatoid arthritis
por: Remuzgo-Martínez, Sara, et al.
Publicado: (2016)

The ER stress inducer DMC enhances TRAIL-induced apoptosis in glioblastoma
por: van Roosmalen, Ingrid A M, et al.
Publicado: (2014)

Lovastatin sensitized human glioblastoma cells to TRAIL-induced apoptosis
por: Chan, David Y. L., et al.
Publicado: (2007)

TRAIL and Taurolidine induce apoptosis and decrease proliferation in human fibrosarcoma
por: Daigeler, Adrien, et al.
Publicado: (2008)

Chalcones Enhance TRAIL-Induced Apoptosis in Prostate Cancer Cells
por: Szliszka, Ewelina, et al.
Publicado: (2009)

Activation of systemic antitumor immunity via TRAIL-induced apoptosis
por: James, Britnie R., et al.
Publicado: (2012)

Modulation of Mcl-1 sensitizes glioblastoma to TRAIL-induced apoptosis
por: Murphy, Á. C., et al.
Publicado: (2013)

Andrographolide sensitizes prostate cancer cells to TRAIL-induced apoptosis
por: Wei, Ruo-Jing, et al.
Publicado: (2018)

LPS promotes resistance to TRAIL-induced apoptosis in pancreatic cancer
por: Beyer, Katharina, et al.
Publicado: (2017)

Alternol Sensitizes Renal Carcinoma Cells to TRAIL-Induced Apoptosis
por: Ren, Yu, et al.
Publicado: (2021)

Improving TRAIL-induced apoptosis in cancers by interfering with histone modifications
por: Zhang, Bao-Jie, et al.
Publicado: (2020)

Heparan sulfate promotes TRAIL-induced tumor cell apoptosis
por: Luo, Yin, et al.
Publicado: (2023)

Sensitizing TRAIL-resistant A549 lung cancer cells and enhancing TRAIL-induced apoptosis with the antidepressant amitriptyline
por: Zinnah, K.M.A., et al.
Publicado: (2021)

The Role of TRAIL in Apoptosis and Immunosurveillance in Cancer
por: Pimentel, Julio M., et al.
Publicado: (2023)

TRAIL-R1 and TRAIL-R2 Mediate TRAIL-Dependent Apoptosis in Activated Primary Human B Lymphocytes
por: Staniek, Julian, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_hk11qtms9fbg7gaar03anltm8v